盟科药业 (688373)
Shanghai MicuRx Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data available
Company NameShanghai MicuRx Pharmaceutical Co., Ltd.
Listing Date2022-08-05
Issue Price8.16RMB
Registered Capital65560.549110k RMB
Legal RepresentativeZHENGYU YUAN (袁征宇)
Registered AddressBuilding 1, Floors 1-4, Edison Road No. 53, China (Shanghai) Pilot Free Trade Zone, Building 1012
IndustryChemical Pharmaceuticals
Main BusinessThe company is an innovative pharmaceutical enterprise focused on treating infectious diseases, possessing global independent intellectual property rights and international competitiveness. It is dedicated to discovering, developing, and commercializing innovative drugs for unmet clinical needs.
Company ProfileShanghai MicuRx Pharmaceutical Co., Ltd. is an innovative pharmaceutical enterprise focused on treating infectious diseases, possessing global independent intellectual property rights and international competitiveness. It is dedicated to discovering, developing, and commercializing innovative drugs for unmet clinical needs. Since its inception, the company has adhered to the philosophy of 'seeking efficacy with good medicine,' focusing on the increasingly severe global issue of bacterial drug resistance. With 'solving clinical challenges and differentiated innovation' as its core competitiveness, its goal is to provide more effective and safer treatment options for the most common and severe drug-resistant bacterial infections in clinical practice.
In the process of conducting clinical trials in China, the company has implemented several pioneering initiatives, laying a solid foundation for raising clinical trial standards and improving product quality in the field of innovative antibacterial drugs in China. The company has established a comprehensive international patent portfolio covering new drug structural formulas, crystal forms, preparation processes, uses, and formulation recipes. It has applied for over 30 invention patents in various countries worldwide, of which 19 have been granted, including 8 domestic and 11 foreign authorizations, providing sufficient and long-lifecycle patent protection for its products.
Stock Details
1. Key Indicators
- Total Shares(W): 65560.55
- Circulating A-Shares(W): 52549.15
- Earnings Per Share(RMB): -0.3000
- Net Assets Per Share(RMB): 0.3928
- Operating Revenue(W RMB): 10398.53
- Total Profit(W RMB): -19340.72
- **Net Profit Attributable to Parent(W RMB) **: -19353.61
- Net Profit Growth Rate(%): 33.56
- Weighted Return on Equity(%): -55.5700
- Operating Cash Flow Per Share(RMB): -0.2530
- Undistributed Profit Per Share(RMB): -3.0479
- Capital Reserve Per Share(RMB): 2.4225
2. Main Business
The main business covers:
- Discovery, development, and commercialization of innovative drugs targeting unmet clinical needs.
3. Company Basic Information
- Company Name: Shanghai MicuRx Pharmaceutical Co., Ltd.
- Listing Date: 2022-08-05
- Industry: Pharmaceutical Manufacturing
- Address: Building 1, 1-4/F, 101, No. 53 Edison Road, China (Shanghai) Pilot Free Trade Zone, and Building 2
- Website: https://www.micurxchina.com/
- Company Profile: The company is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs, committed to addressing unmet clinical needs. The company completed its joint-stock reform in 2020 and was listed on the STAR Market in 2022.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Best Idea International Limited | Corporate Entity | 5843.90 | 11.12 |
| 2 | JSR Limited | Corporate Entity | 3084.45 | 5.87 |
| 3 | MicuRx(HK)Limited | Corporate Entity | 2612.71 | 4.97 |
| 4 | GP TMT Holdings Limited | Corporate Entity | 1837.13 | 3.50 |
| 5 | Huagai Capital Co., Ltd. - Beijing Huagai Xincheng Yuanhang Medical Industry Investment Partnership (Limited Partnership) | Corporate Entity | 1288.38 | 2.45 |
| 6 | Xinyi Youmaikesi Financial Consulting Center (Limited Partnership) | Corporate Entity | 713.07 | 1.36 |
| 7 | GF Securities Co., Ltd. | Securities Firm | 691.45 | 1.32 |
| 8 | Beijing Tidesun Private Fund Management Co., Ltd. - Tidesun Investment Zhisheng Quantitative 1 Private Securities Investment Fund | Private Securities Investment Fund | 650.71 | 1.24 |
| 9 | Minsheng Jianyin Pension Services Flexible Allocation Mixed Securities Investment Fund | Fund | 2.26 | 0.00 |
5. Concept Sectors
- Innovative Drugs
- Margin Trading & Securities Lending
- High Price-to-Book Ratio
- Loss-Making Stocks
- Heavily Held by Securities Firms
- Private Placement Plan
- Consecutive Losses
- Below IPO Price
- Planned Reduction
- STAR Market Growth Layer
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information